UN Migration Agency Selects Kony to Accelerate Digital Strategy to Reach More Migrants
Kony, Inc., a leading enterprise mobility and digital applications company, announced that it has been selected by IOM, the UN Migration Agency, to accelerate its digital strategy and support its vision to provide information and humanitarian services to more migrants and government agencies.
As the world’s leading intergovernmental agency dedicated to the wellbeing, safety and engagement of migrants, IOM will use the Kony AppPlatform to deliver mobile apps, including the MigApp, to provide key information and humanitarian services to migrants worldwide.
IOM works closely with governmental, intergovernmental and non-governmental partners. With 166 member states, over 400 field locations and more than 90 per cent of its staff deployed in the field, mobile applications play a critical role in the success of IOM as one of the lead responders to the world’s worst humanitarian emergencies.
IOM is dedicated to enabling humane and orderly migration, promoting international cooperation on migration, assisting in the development of practical solutions for migration issues and providing humanitarian assistance to migrants, including refugees and internally displaced persons.
Many migrants encounter tremendous challenges throughout their journeys and though many migrants, especially those forcibly displaced or migrating irregularly, carry very few personal possessions, most people do carry a smartphone, which can be a gateway to reliable and practical information on migration and humanitarian services.
IOM intends to use the Kony AppPlatform to build multiple apps to support its mission, not only to empower migrants to take charge of their own journey, but also reduce their dependency on unauthorized entities and processes that are not beneficial to the migrants.
“Since our establishment in 1951, IOM upholds the belief that migration builds resilience,” said Bernardo Mariano, IOM’s Director of the Information and Communication Technology Division. “Migrants are agents of change and development. Our ultimate objective is to reduce the human and financial costs of migration through increased engagement with migrants. We look forward to leveraging Kony’s technology, expertise and secure mobile applications to further our commitment to the principle that humane and orderly migration benefits not just migrants but all of society,” he added.
IOM selected the Kony platform to develop and deliver the MigApp, with the goal of reaching 1 billion migrants and achieving 1 million downloads of the app by 2018. The MigApp is a one-stop-shop application that users can download to their mobile phones for free to access information and services relevant to their migration process.
The goal is to help migrants make informed decisions, provide them with access to services related to their migration process, and allow access to IOM programmes. Features planned for the first phase of MigApp include:
- Remittance comparison allowing migrants to find cost-effective ways to send money home;
- Access to up-to-date practical information on IOM programmes and services;
- “I am a Migrant” space where migrants can share their experiences, tell their stories and upload photos to share with other MigApp users;
- Notification services providing alerts on emergencies, health-care information, and other important information related to their location;
- IOM news;
- Online registration enabling IOM to capture data which can be used to analyse migration patterns and trends.
“We are thrilled to partner with all global leaders, and we take special pride in supporting the mission of the UN Migration Agency,” said Thomas E. Hogan, Chairman and Chief Executive Officer, Kony, Inc. “As a global citizen deeply committed to the communities we serve, our contribution to humanitarian services for the world’s migrants is both important and rewarding.”
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 11:00 | Pressemelding
Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines
Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 08:10 | Pressemelding
Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest
Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 15:13 | Pressemelding
Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,
Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 14:00 | Pressemelding
Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With
Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 13:41 | Pressemelding
Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel
Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 12:00 | Pressemelding
Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i